![](/images/general/no_picture/200_user.png)
Saul Rodriguez
Supervisory Patent Examiner (ID: 17499, Phone: (571)272-7097 , Office: P/3652 )
Most Active Art Unit | 3681 |
Art Unit(s) | 3681, 3502, 3652, 3622 |
Total Applications | 1074 |
Issued Applications | 910 |
Pending Applications | 29 |
Abandoned Applications | 135 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 5771563
[patent_doc_number] => 20050267014
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2005-12-01
[patent_title] => 'Pharmaceutical composition comprising factor VII polypeptides and tranexamic acid'
[patent_app_type] => utility
[patent_app_number] => 11/191525
[patent_app_country] => US
[patent_app_date] => 2005-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 17588
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0267/20050267014.pdf
[firstpage_image] =>[orig_patent_app_number] => 11191525
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/191525 | Pharmaceutical composition comprising factor VII polypeptides and tranexamic acid | Jul 27, 2005 | Abandoned |
11/049616 | Novel human thrombospondin repeat proteins and polynucleotides encoding the same | Feb 1, 2005 | Abandoned |
11/028510 | Novel human alpha macroglobulin family proteins and polynucleotides encoding the same | Jan 2, 2005 | Abandoned |
Array
(
[id] => 6905595
[patent_doc_number] => 20050100990
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2005-05-12
[patent_title] => 'Factor VIII compositions and methods'
[patent_app_type] => utility
[patent_app_number] => 10/968286
[patent_app_country] => US
[patent_app_date] => 2004-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 34520
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0100/20050100990.pdf
[firstpage_image] =>[orig_patent_app_number] => 10968286
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/968286 | Factor VIII compositions and methods | Oct 19, 2004 | Issued |
Array
(
[id] => 642213
[patent_doc_number] => 07122634
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2006-10-17
[patent_title] => 'Modified factor VIII'
[patent_app_type] => utility
[patent_app_number] => 10/938414
[patent_app_country] => US
[patent_app_date] => 2004-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 8
[patent_no_of_words] => 31174
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/122/07122634.pdf
[firstpage_image] =>[orig_patent_app_number] => 10938414
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/938414 | Modified factor VIII | Sep 9, 2004 | Issued |
Array
(
[id] => 7466063
[patent_doc_number] => 20040198660
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-10-07
[patent_title] => 'Tissue factor antagonist and protein C polypeptide compositions'
[patent_app_type] => new
[patent_app_number] => 10/700778
[patent_app_country] => US
[patent_app_date] => 2003-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18163
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0198/20040198660.pdf
[firstpage_image] =>[orig_patent_app_number] => 10700778
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/700778 | Tissue factor antagonist and protein C polypeptide compositions | Nov 3, 2003 | Abandoned |
90/006823 | STABILIZED FACTOR VIII PREPARATIONS | Oct 20, 2003 | Issued |
Array
(
[id] => 956149
[patent_doc_number] => 06955899
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2005-10-18
[patent_title] => 'Adipocyte complement related protein zacrp13'
[patent_app_type] => utility
[patent_app_number] => 10/688570
[patent_app_country] => US
[patent_app_date] => 2003-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39395
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/955/06955899.pdf
[firstpage_image] =>[orig_patent_app_number] => 10688570
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/688570 | Adipocyte complement related protein zacrp13 | Oct 16, 2003 | Issued |
Array
(
[id] => 7281540
[patent_doc_number] => 20040063917
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-04-01
[patent_title] => 'Modified erythropoietin (epo) with reduced immunogenicity'
[patent_app_type] => new
[patent_app_number] => 10/467115
[patent_app_country] => US
[patent_app_date] => 2003-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11850
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0063/20040063917.pdf
[firstpage_image] =>[orig_patent_app_number] => 10467115
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/467115 | Modified erythropoietin (epo) with reduced immunogenicity | Aug 4, 2003 | Abandoned |
Array
(
[id] => 7394125
[patent_doc_number] => 20040038352
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-02-26
[patent_title] => 'Method for fermentative production of amino acids and amino acid derivatives of the phosphoglycerate family'
[patent_app_type] => new
[patent_app_number] => 10/620487
[patent_app_country] => US
[patent_app_date] => 2003-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 3888
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0038/20040038352.pdf
[firstpage_image] =>[orig_patent_app_number] => 10620487
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/620487 | Method for fermentative production of amino acids and amino acid derivatives of the phosphoglycerate family | Jul 15, 2003 | Abandoned |
Array
(
[id] => 7224546
[patent_doc_number] => 20040072755
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-04-15
[patent_title] => 'TF antagonist'
[patent_app_type] => new
[patent_app_number] => 10/617500
[patent_app_country] => US
[patent_app_date] => 2003-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 19862
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0072/20040072755.pdf
[firstpage_image] =>[orig_patent_app_number] => 10617500
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/617500 | TF antagonist | Jul 10, 2003 | Abandoned |
Array
(
[id] => 7207983
[patent_doc_number] => 20040087643
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-05-06
[patent_title] => 'Method of treating thrombocytopenic purpura and hemolytic uremic syndrome'
[patent_app_type] => new
[patent_app_number] => 10/602936
[patent_app_country] => US
[patent_app_date] => 2003-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4338
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0087/20040087643.pdf
[firstpage_image] =>[orig_patent_app_number] => 10602936
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/602936 | Method of treating thrombocytopenic purpura and hemolytic uremic syndrome | Jun 23, 2003 | Abandoned |
Array
(
[id] => 493970
[patent_doc_number] => 07211558
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2007-05-01
[patent_title] => 'Compositions and methods for the treatment of hemophilia A'
[patent_app_type] => utility
[patent_app_number] => 10/445235
[patent_app_country] => US
[patent_app_date] => 2003-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 8637
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 976
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/211/07211558.pdf
[firstpage_image] =>[orig_patent_app_number] => 10445235
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/445235 | Compositions and methods for the treatment of hemophilia A | May 21, 2003 | Issued |
Array
(
[id] => 690772
[patent_doc_number] => 07074755
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2006-07-11
[patent_title] => 'Erythropoietin conjugate compounds with extended half-lives'
[patent_app_type] => utility
[patent_app_number] => 10/439870
[patent_app_country] => US
[patent_app_date] => 2003-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 6628
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/074/07074755.pdf
[firstpage_image] =>[orig_patent_app_number] => 10439870
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/439870 | Erythropoietin conjugate compounds with extended half-lives | May 16, 2003 | Issued |
Array
(
[id] => 7367250
[patent_doc_number] => 20040006020
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-01-08
[patent_title] => 'Pharmaceutical composition comprising a factor VII polypeptide and epsilon-aminocaproic acid'
[patent_app_type] => new
[patent_app_number] => 10/437522
[patent_app_country] => US
[patent_app_date] => 2003-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 17573
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0006/20040006020.pdf
[firstpage_image] =>[orig_patent_app_number] => 10437522
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/437522 | Pharmaceutical composition comprising a factor VII polypeptide and epsilon-aminocaproic acid | May 13, 2003 | Abandoned |
Array
(
[id] => 7367253
[patent_doc_number] => 20040006021
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-01-08
[patent_title] => 'Pharmaceutical composition comprising factor Vll polypeptides and tranexamic acid'
[patent_app_type] => new
[patent_app_number] => 10/437674
[patent_app_country] => US
[patent_app_date] => 2003-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 17785
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0006/20040006021.pdf
[firstpage_image] =>[orig_patent_app_number] => 10437674
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/437674 | Pharmaceutical composition comprising factor Vll polypeptides and tranexamic acid | May 13, 2003 | Abandoned |
Array
(
[id] => 7232722
[patent_doc_number] => 20050256035
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2005-11-17
[patent_title] => 'Ctp-extended erythropoietin'
[patent_app_type] => utility
[patent_app_number] => 10/514302
[patent_app_country] => US
[patent_app_date] => 2003-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 1081
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0256/20050256035.pdf
[firstpage_image] =>[orig_patent_app_number] => 10514302
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/514302 | Ctp-extended erythropoietin | May 12, 2003 | Abandoned |
Array
(
[id] => 7448402
[patent_doc_number] => 20040009902
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-01-15
[patent_title] => 'CTP extended erythropoietin'
[patent_app_type] => new
[patent_app_number] => 10/438277
[patent_app_country] => US
[patent_app_date] => 2003-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 1099
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0009/20040009902.pdf
[firstpage_image] =>[orig_patent_app_number] => 10438277
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/438277 | CTP extended erythropoietin | May 12, 2003 | Abandoned |
Array
(
[id] => 7297180
[patent_doc_number] => 20040214748
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-10-28
[patent_title] => 'Hemoglobin conjugates'
[patent_app_type] => new
[patent_app_number] => 10/420966
[patent_app_country] => US
[patent_app_date] => 2003-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2306
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0214/20040214748.pdf
[firstpage_image] =>[orig_patent_app_number] => 10420966
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/420966 | Hemoglobin conjugates | Apr 22, 2003 | Issued |
Array
(
[id] => 7397964
[patent_doc_number] => 20040018560
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-01-29
[patent_title] => 'Crystallized LXR polypeptide in complex with a ligand and screening methods employing same'
[patent_app_type] => new
[patent_app_number] => 10/418007
[patent_app_country] => US
[patent_app_date] => 2003-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 181580
[patent_no_of_claims] => 105
[patent_no_of_ind_claims] => 12
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0018/20040018560.pdf
[firstpage_image] =>[orig_patent_app_number] => 10418007
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/418007 | Crystallized LXR polypeptide in complex with a ligand and screening methods employing same | Apr 16, 2003 | Abandoned |